Document Report Card

Basic Information

ID: ALA4665722

Journal: Bioorg Med Chem Lett

Title: Discovery of a novel selective water-soluble SMAD3 inhibitor as an antitumor agent.

Authors: Wu N,Lian G,Sheng J,Wu D,Yu X,Lan H,Hu W,Yang Z

Abstract: Targeting the SMAD3 protein is an attractive therapeutic strategy for treating cancer, as it avoids the potential toxicities due to targeting the TGF-β signaling pathway upstream. Compound SIS3 was the first selective SMAD3 inhibitor developed that had acceptable activity, but its poor water solubility limited its development. Here, a series of SIS3 analogs was created to investigate the structure-activity relationship for inhibiting the activation of SMAD3. On the basis of this SAR, further optimization generated a water-soluble compound, 16d, which was capable of effectively blocking SMAD3 activation in vitro and had similar NK cell-mediated anticancer effects in vivo to its parent SIS3. This study not only provided a preferable lead compound, 16d, for further drug discovery or a potential tool to study SMAD3 biology, but also proved the effectiveness of our strategy for water-solubility driven optimization.

CiteXplore: 32738967

DOI: 10.1016/j.bmcl.2020.127396